Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,875,732
  • Shares Outstanding, K 57,795
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,530 K
  • EBIT $ -248 M
  • EBITDA $ -265 M
  • 60-Month Beta -1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.04

Options Overview Details

View History
  • Implied Volatility 72.34% (-0.67%)
  • Historical Volatility 209.94%
  • IV Percentile 11%
  • IV Rank 5.50%
  • IV High 297.52% on 12/05/25
  • IV Low 59.22% on 09/15/25
  • Expected Move (DTE 4) 4.59 (6.84%)
  • Put/Call Vol Ratio 0.73
  • Today's Volume 1,154
  • Volume Avg (30-Day) 3,737
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 61,201
  • Open Int (30-Day) 42,905
  • Expected Range 62.47 to 71.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 7
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -63.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.94 +116.74%
on 12/04/25
94.90 -29.34%
on 12/08/25
+31.14 (+86.69%)
since 11/12/25
3-Month
20.04 +234.63%
on 09/16/25
94.90 -29.34%
on 12/08/25
+46.15 (+220.71%)
since 09/12/25
52-Week
13.22 +407.26%
on 04/09/25
94.90 -29.34%
on 12/08/25
+35.35 (+111.48%)
since 12/12/24

Most Recent Stories

More News
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight...

GPCR : 67.06 (-0.56%)
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)...

GPCR : 67.06 (-0.56%)
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. The company’s shares closed yesterday at $26.62.Elevate...

GPCR : 67.06 (-0.56%)
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

GPCR : 67.06 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 71.81
2nd Resistance Point 70.36
1st Resistance Point 68.71
Last Price 67.06
1st Support Level 65.61
2nd Support Level 64.16
3rd Support Level 62.51

See More

52-Week High 94.90
Last Price 67.06
Fibonacci 61.8% 63.70
Fibonacci 50% 54.06
Fibonacci 38.2% 44.42
52-Week Low 13.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar